The role of carboplatin in cervical and endometrial cancers is being assessed through clinical trials. Preliminary results indicate some activity against both of these gynecologic tumors. Carboplatin is also being integrated into combination regimens with other active drugs. In the treatment of cervical cancer, it is used as part of combined-modality regimens prior to radiotherapy. Patients have shown better subjective tolerance to carboplatin than to cisplatin. This finding may facilitate the widespread implementation of carboplatin-based combinations.